A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors
Clinical trial NCT05996445 · TERMINATED
Trial details
- NCT number
- NCT05996445
- Sponsor
- Xencor, Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-28
- Primary completion
- 2024-05-21
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.